Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 11, 2007, Pages 2154-2158

  Koue, Toshiko ^a,b   Kubo, Masanori ^a   Funaki, Tomoo ^a   Fukuda, Tsuyoshi ^c   Azuma, Junichi ^c   Takaai, Mari ^b   Kayano, Yuichiro ^b   Hashimoto, Yukiya ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Aripiprazole; CYP2D6 genotype; Itraconazole; Nonlinear mixed effect model; Pharmacokinetic; Two compartment model

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; ITRACONAZOLE;

ADULT; ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NONLINEAR SYSTEM; NORMAL HUMAN;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BAYES THEOREM; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; ITRACONAZOLE; JAPAN; MALE; METABOLIC CLEARANCE RATE; MODELS, THEORETICAL; PIPERAZINES; POLYMORPHISM, GENETIC; QUINOLONES; SOFTWARE; TABLETS;

EID: 36048992549     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.2154     Document Type: Article

References (21)

1. Oshiro Y., Sato S., Kurahashi N., Tanaka T., Kikuchi T., Tottori K., Uwahodo Y., Nishi T., J. Med. Chem., 41, 658-667 (1998).
2. El-Sayeh H. G., Morganti C., Adams C. E., Br. J. Psychiatry, 189, 102-108 (2006).
3. Burris K. D., Molski T. F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F. D., Molinoff P. B., J. Pharmacol. Exp. Ther., 302, 381-389 (2002).
4. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C. A., Eur. J. Pharmacol., 441, 137-140 (2002).
5. Package insert of Abilify® (Aripiprazole, U.S.), April 2004 Revision, Otsuka America Pharmaceutical, Inc., Rockville, MD 20850, U.S.A. and Bristol-Myers Squibb Co., Princeton, NJ 08543, U.S.A.
6. Ozawa S., Soyama A., Saeki M., Fukushima-Uesaka H., Itoda M., Koyano S., Sai K., Ohno Y., Saito Y., Sawada J., Drug Metab. Pharmacokinet., 19, 83-95 (2004).
7. Nishida Y., Fukuda T., Yamamoto I., Azuma J., Pharmacogenetics, 10, 567-570 (2000).
8. Sheiner L. B., Ludden T. M., Annu. Rev. Pharmacol. Toxicol., 32, 185-209 (1992).
9. Beal S. L., Boeckmann A. J., Sheiner L. B., "NONMEM Users Guides: NONMEM Project Group," University of California, San Francisco, 1992.
10. Hashimoto Y., Ozaki J., Koue T., Odani A., Yasuhara M., Hori R., Pharm. Res., 11, 545-548 (1994).
11. Hashimoto Y., Koue T., Otsuki Y., Yasuhara M., Hori R., Inui K., J. Pharmacokinet. Biopharm., 23, 205-216 (1995).
12. Honda M., Itoh H., Suzuki T., Hashimoto Y., Biol. Pharm. Bull., 29, 2460-2464 (2006).
13. Kubo M., Koue T., Inaba A., Takeda H., Maune H., Fukuda T., Azuma J., Drug Metab. Pharmacokinet., 20, 55-64 (2005).
14. Kubo M., Koue T., Maune H., Fukuda T., Azuma J., Drug Metab. Pharmacokinet., in press.
15. Taguchi M., Nozawa T., Mizumaki K., Inoue H., Tahara K., Takesono C., Hashimoto Y., Biol. Pharm. Bull., 27, 1642-1648 (2004).
16. Zanger U. M., Fischer J., Raimundo S., Stuven T., Evert B. O., Schwab M., Eichelbaum M., Pharmacogenetics, 11, 573-585 (2001).
17. Toscano C., Klein K., Blievernicht J., Schaeffeler E., Saussele T., Raimundo S., Eichelbaum M., Schwab M., Zanger U. M., Pharmacogenet. Genomics, 16, 755-766 (2006).
18. Rowland M., Benet L. Z., Graham G. G., J. Pharmacokinet. Biopharm., 1, 123-136 (1973).
19. Wilkinson G. R., Shand D. G., Clin. Pharmacol. Ther., 18, 377-390 (1975).
20. Wilkinson G. R., Pharmacol. Rev., 39, 1-47 (1987).
21. Øie S., Tozer T. N., J. Pharm. Sci., 68, 1203-1205 (1979).